NeoGenomics Inc (NEO) - Net Assets
Based on the latest financial reports, NeoGenomics Inc (NEO) has net assets worth $836.56 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.36 Billion) and total liabilities ($523.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NeoGenomics Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $836.56 Million |
| % of Total Assets | 61.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | -24.52% |
| 10-Year Change | 348.33% |
| Growth Volatility | 992.46 |
NeoGenomics Inc - Net Assets Trend (2000–2025)
This chart illustrates how NeoGenomics Inc's net assets have evolved over time, based on quarterly financial data. Also explore NEO total asset value for the complete picture of this company's asset base.
Annual Net Assets for NeoGenomics Inc (2000–2025)
The table below shows the annual net assets of NeoGenomics Inc from 2000 to 2025. For live valuation and market cap data, see market value of NeoGenomics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $836.56 Million | -7.29% |
| 2024-12-31 | $902.34 Million | -4.16% |
| 2023-12-31 | $941.54 Million | -5.66% |
| 2022-12-31 | $998.02 Million | -9.95% |
| 2021-12-31 | $1.11 Billion | +59.63% |
| 2020-12-31 | $694.29 Million | +36.83% |
| 2019-12-31 | $507.41 Million | +58.35% |
| 2018-12-31 | $320.44 Million | +55.91% |
| 2017-12-31 | $205.53 Million | +10.15% |
| 2016-12-31 | $186.60 Million | -21.64% |
| 2015-12-31 | $238.11 Million | +294.19% |
| 2014-12-31 | $60.41 Million | +178.22% |
| 2013-12-31 | $21.71 Million | +135.58% |
| 2012-12-31 | $9.22 Million | +56.28% |
| 2011-12-31 | $5.90 Million | +88.10% |
| 2010-12-31 | $3.13 Million | -44.45% |
| 2009-12-31 | $5.64 Million | +275.94% |
| 2008-12-31 | $1.50 Million | -35.36% |
| 2007-12-31 | $2.32 Million | +4159.67% |
| 2006-12-31 | $54.51K | +105.48% |
| 2005-12-31 | $-994.94K | -133.20% |
| 2004-12-31 | $-426.65K | -16.00% |
| 2003-12-31 | $-367.80K | -1675.51% |
| 2002-12-31 | $23.34K | +122.26% |
| 2001-12-31 | $-104.87K | +16.00% |
| 2000-12-31 | $-124.84K | -- |
Equity Component Analysis
This analysis shows how different components contribute to NeoGenomics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43235917400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $129.00K | 0.02% |
| Other Comprehensive Income | $4.00K | 0.00% |
| Other Components | $1.27 Billion | 151.84% |
| Total Equity | $836.56 Million | 100.00% |
NeoGenomics Inc Competitors by Market Cap
The table below lists competitors of NeoGenomics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sinoseal Holding Co Ltd
SHE:300470
|
$1.03 Billion |
|
Strides Pharma Science Limited
NSE:STAR
|
$1.03 Billion |
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
$1.03 Billion |
|
Wuxi ETEK Microelectronics Co Ltd
SHG:688601
|
$1.03 Billion |
|
Quechen Silicon Chemical Co. Ltd.
SHG:605183
|
$1.03 Billion |
|
Sinodata Co Ltd
SHE:002657
|
$1.03 Billion |
|
São Martinho S.A
SA:SMTO3
|
$1.03 Billion |
|
E2open Parent Holdings Inc
NYSE:ETWO
|
$1.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NeoGenomics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 902,339,000 to 836,562,000, a change of -65,777,000 (-7.3%).
- Net loss of 108,025,000 reduced equity.
- New share issuances of 962,000 increased equity.
- Other comprehensive income increased equity by 210,000.
- Other factors increased equity by 41,076,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-108.03 Million | -12.91% |
| Share Issuances | $962.00K | +0.11% |
| Other Comprehensive Income | $210.00K | +0.03% |
| Other Changes | $41.08 Million | +4.91% |
| Total Change | $- | -7.29% |
Book Value vs Market Value Analysis
This analysis compares NeoGenomics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.29x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-0.80 | $9.44 | x |
| 2001-12-31 | $-0.14 | $9.44 | x |
| 2002-12-31 | $0.03 | $9.44 | x |
| 2003-12-31 | $-0.13 | $9.44 | x |
| 2004-12-31 | $-0.10 | $9.44 | x |
| 2005-12-31 | $-0.22 | $9.44 | x |
| 2006-12-31 | $0.01 | $9.44 | x |
| 2007-12-31 | $0.37 | $9.44 | x |
| 2008-12-31 | $0.24 | $9.44 | x |
| 2009-12-31 | $0.81 | $9.44 | x |
| 2010-12-31 | $0.42 | $9.44 | x |
| 2011-12-31 | $0.69 | $9.44 | x |
| 2012-12-31 | $0.95 | $9.44 | x |
| 2013-12-31 | $2.06 | $9.44 | x |
| 2014-12-31 | $5.39 | $9.44 | x |
| 2015-12-31 | $19.67 | $9.44 | x |
| 2016-12-31 | $2.41 | $9.44 | x |
| 2017-12-31 | $12.94 | $9.44 | x |
| 2018-12-31 | $17.50 | $9.44 | x |
| 2019-12-31 | $24.49 | $9.44 | x |
| 2020-12-31 | $31.05 | $9.44 | x |
| 2021-12-31 | $46.19 | $9.44 | x |
| 2022-12-31 | $40.17 | $9.44 | x |
| 2023-12-31 | $37.51 | $9.44 | x |
| 2024-12-31 | $35.62 | $9.44 | x |
| 2025-12-31 | $32.65 | $9.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NeoGenomics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -12.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -14.85%
- • Asset Turnover: 0.53x
- • Equity Multiplier: 1.63x
- Recent ROE (-12.91%) is above the historical average (-123.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -384.31% | 1357.01x | 0.00x | $-957.52K |
| 2001 | 0.00% | -807800.00% | 0.01x | 0.00x | $-8.07 Million |
| 2002 | -2529.55% | -631.64% | 0.21x | 19.18x | $-592.86K |
| 2003 | 0.00% | -144.88% | 0.73x | 0.00x | $-499.22K |
| 2004 | 0.00% | -146.75% | 0.94x | 0.00x | $-776.33K |
| 2005 | 0.00% | -52.89% | 1.75x | 0.00x | $-897.51K |
| 2006 | -238.47% | -2.01% | 2.07x | 57.45x | $-135.45K |
| 2007 | -145.56% | -29.38% | 1.76x | 2.81x | $-3.61 Million |
| 2008 | -92.13% | -6.91% | 2.74x | 4.86x | $-1.53 Million |
| 2009 | -39.75% | -7.61% | 2.28x | 2.29x | $-2.81 Million |
| 2010 | -105.36% | -9.61% | 2.52x | 4.35x | $-3.62 Million |
| 2011 | -19.96% | -2.71% | 2.18x | 3.38x | $-1.77 Million |
| 2012 | 0.71% | 0.11% | 1.99x | 3.26x | $-856.60K |
| 2013 | 9.36% | 3.06% | 1.67x | 1.84x | $-138.10K |
| 2014 | 1.87% | 1.30% | 1.07x | 1.34x | $-4.91 Million |
| 2015 | -1.06% | -2.54% | 0.27x | 1.55x | $-26.35 Million |
| 2016 | -3.29% | -2.52% | 0.72x | 1.81x | $-24.80 Million |
| 2017 | -0.19% | -0.16% | 0.70x | 1.67x | $-20.95 Million |
| 2018 | 0.82% | 0.95% | 0.55x | 1.58x | $-29.40 Million |
| 2019 | 1.58% | 1.96% | 0.58x | 1.40x | $-42.73 Million |
| 2020 | 0.60% | 0.94% | 0.45x | 1.42x | $-65.26 Million |
| 2021 | -0.75% | -1.72% | 0.26x | 1.69x | $-119.17 Million |
| 2022 | -14.45% | -28.30% | 0.29x | 1.74x | $-244.05 Million |
| 2023 | -9.34% | -14.87% | 0.35x | 1.79x | $-182.12 Million |
| 2024 | -8.72% | -11.92% | 0.40x | 1.82x | $-168.96 Million |
| 2025 | -12.91% | -14.85% | 0.53x | 1.63x | $-191.68 Million |
Industry Comparison
This section compares NeoGenomics Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $543,908,184
- Average return on equity (ROE) among peers: -221.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NeoGenomics Inc (NEO) | $836.56 Million | 0.00% | 0.63x | $1.03 Billion |
| Agilent Technologies Inc (A) | $2.51 Billion | -1.24% | 2.04x | $32.42 Billion |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.49 Million | -115.35% | 0.92x | $7.19 Million |
| Applied DNA Sciences Inc (APDN) | $11.11 Million | -144.24% | 0.30x | $3.99 Million |
| Biodesix Inc (BDSX) | $4.58 Million | -1138.56% | 20.64x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $7.28 Million | -204.87% | 0.51x | $9.85 Million |
| Biocept Inc. (BIOCQ) | $11.20 Million | -224.43% | 0.58x | $262.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $30.47 Million | -271.32% | 5.29x | $3.21 Billion |
| Burning Rock Biotech Ltd (BNR) | $2.42 Billion | -16.82% | 0.10x | $154.44 Million |
| CareDx Inc (CDNA) | $430.91 Million | -17.78% | 0.26x | $1.00 Billion |
| Check Cap Ltd (CHEK) | $13.03 Million | -81.27% | 0.18x | $9.42 Million |
About NeoGenomics Inc
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to dise… Read more